These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 21421040)
21. Drug discovery in the next decade: innovation needed ASAP. Bennani YL Drug Discov Today; 2011 Sep; 16(17-18):779-92. PubMed ID: 21704185 [TBL] [Abstract][Full Text] [Related]
22. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'. Campbell JB IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146 [TBL] [Abstract][Full Text] [Related]
23. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Waring MJ; Arrowsmith J; Leach AR; Leeson PD; Mandrell S; Owen RM; Pairaudeau G; Pennie WD; Pickett SD; Wang J; Wallace O; Weir A Nat Rev Drug Discov; 2015 Jul; 14(7):475-86. PubMed ID: 26091267 [TBL] [Abstract][Full Text] [Related]
24. What makes a good drug target? Gashaw I; Ellinghaus P; Sommer A; Asadullah K Drug Discov Today; 2011 Dec; 16(23-24):1037-43. PubMed ID: 21945861 [TBL] [Abstract][Full Text] [Related]
25. How to revive breakthrough innovation in the pharmaceutical industry. Munos BH; Chin WW Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677 [TBL] [Abstract][Full Text] [Related]
26. Preclinical formulations for discovery and toxicology: physicochemical challenges. Neervannan S Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):715-31. PubMed ID: 17014391 [TBL] [Abstract][Full Text] [Related]
27. The role of translational bioinformatics in drug discovery. Buchan NS; Rajpal DK; Webster Y; Alatorre C; Gudivada RC; Zheng C; Sanseau P; Koehler J Drug Discov Today; 2011 May; 16(9-10):426-34. PubMed ID: 21402166 [TBL] [Abstract][Full Text] [Related]
28. Strategies for conducting ADME studies during lead generation in the drug discovery process. Cramer JW; Mattioni BE; Savin KA IDrugs; 2010 Dec; 13(12):857-61. PubMed ID: 21154143 [TBL] [Abstract][Full Text] [Related]
29. New ways of insulin delivery. Heinemann L Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662 [TBL] [Abstract][Full Text] [Related]
30. Challenges of antibacterial discovery revisited. Gwynn MN; Portnoy A; Rittenhouse SF; Payne DJ Ann N Y Acad Sci; 2010 Dec; 1213():5-19. PubMed ID: 21058956 [TBL] [Abstract][Full Text] [Related]
31. Ask the experts: the challenges and benefits of flow chemistry to optimize drug development. Anderson N; Gernaey KV; Jamison TF; Kircher M; Wiles C; Leadbeater NE; Sandford G; Richardson P Future Med Chem; 2012 Sep; 4(14):1779-89. PubMed ID: 23043475 [TBL] [Abstract][Full Text] [Related]
32. Challenges of biomarkers in drug discovery and development. Goodsaid F Expert Opin Drug Discov; 2012 Jun; 7(6):457-61. PubMed ID: 22471322 [TBL] [Abstract][Full Text] [Related]
33. Recent advances in physicochemical and ADMET profiling in drug discovery. Wang J; Skolnik S Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823 [TBL] [Abstract][Full Text] [Related]
34. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. Palucki M; Higgins JD; Kwong E; Templeton AC J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889 [No Abstract] [Full Text] [Related]
35. From biomarker strategies to biomarker activities and back. van Gool AJ; Henry B; Sprengers ED Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413 [TBL] [Abstract][Full Text] [Related]
36. Opportunities and challenges in the discovery of new central nervous system drugs. Krause JE; Chenard BL Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381 [TBL] [Abstract][Full Text] [Related]
37. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery. Thomas CE; Will Y Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913 [TBL] [Abstract][Full Text] [Related]
38. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition. Giri S; Bader A Drug Discov Today; 2011 May; 16(9-10):382-97. PubMed ID: 21354326 [TBL] [Abstract][Full Text] [Related]
39. Drug research: from the idea to the product. Kuhlmann J Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711 [TBL] [Abstract][Full Text] [Related]
40. Organizing for innovation: towards successful translational research. West W; Nightingale P Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]